Chen ZH, et al. - For hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI), researchers assessed the effectiveness and safety of adjuvant transarterial chemoembolization (TACE) and hepatic resection (HR) alone via 12 trials involving 2,190 patients from the PubMed, EMBASE, Cochrane Library, VIP, Wan Fang, and Sino Med databases. Findings suggest that HCC patients with MVI could achieve improved overall survival and disease-free survival with adjuvant TACE vs HR alone and researchers recommend adjuvant TACE for selected HCC patients with MVI. HCC patients with MVI with tumor diameter >5 cm or multinodular tumors could benefit from adjuvant TACE.